0001104659-26-058981 | 6-K | XBRL Viewer


	March 31,	December 31,
	2026	2025
	€1,000	€1,000
Collaboration receivables	406	3,358
Prepayments	3,178	2,627
Accrued income from Rett Syndrome Research Trust	502	502
Other receivables	318	313
Total	4,404	6,800

Current receivables from collaboration agreements

prqr_CurrentReceivablesFromCollaborationAgreements

€ 406,000

Current receivables from collaboration agreements

prqr_CurrentReceivablesFromCollaborationAgreements

3,358,000

Current borrowings excluding accrued interest

prqr_CurrentBorrowingsExcludingAccruedInterest

2,899,000

Conditional Waiver of Debt, Total

prqr_ConditionalWaiverOfDebtTotal

€ 4,292,000

Area Of Property Under Lease

prqr_AreaOfPropertyUnderLease

4,818

Lease extension term

prqr_LeaseExtensionTerm

1 year

Authorized share capital value

prqr_AuthorizedShareCapitalValue

€ 13,600,000

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

3,989,976

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

9,381,586

Discount on Issue of Shares

prqr_DiscountOnIssueOfShares

€ 480,000

Discount on Issue of Shares

prqr_DiscountOnIssueOfShares

€ 451,000

Additional consideration to be received if counterparty exercises option to expand partnership

prqr_AdditionalConsiderationToBeReceivedIfCounterpartyExercisesOptionToExpandPartnership

€ 50,000,000

Number of performance obligations in collaboration agreement

prqr_NumberOfPerformanceObligationsInCollaborationAgreement

Value of milestones reached during the period

prqr_ValueOfMilestonesReachedDuringPeriod

€ 0

Shelf registration statement, 2024 [Member]

Maximum offering price in shelf registration statement

prqr_MaximumOfferingPriceInShelfRegistrationStatement

€ 300,000,000

Share purchase agreement with Eli Lilly and Company [Member]

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

3,523,538

Purchase price cap, share purchase agreement

prqr_PurchasePriceCapSharePurchaseAgreement

€ 15,000,000

At the market offerings with Cantor Fitzgerald and Co under shelf registration statement [Member]

Maximum offering price in shelf registration statement

prqr_MaximumOfferingPriceInShelfRegistrationStatement

€ 75,000,000

Percentage of commission payable for gross proceeds from sales agreement

prqr_PercentageOfCommissionPayableForGrossProceedsFromSalesAgreement

3.00%

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

October 2024 underwritten public offering [Member]

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

18,000,000

IFRS Sale Of Stock Price Per Share

prqr_IfrsSaleOfStockPricePerShare

€ 3.5

Net proceeds from issuing shares

prqr_NetProceedsFromIssuingShares

€ 60,235,000

Underwriters' option in connection to October 2024 underwritten public offering [Member]

Duration of underwriters' option

prqr_DurationOfUnderwritersOption

30 days

Ifrs Stock Issued During Period, Shares, New Issues

prqr_IfrsStockIssuedDuringPeriodSharesNewIssues

1,940,072

Number of shares callable for options issued

prqr_NumberOfSharesCallableForOptionsIssued

2,700,000

Pontifax and Kreos warrants [Member]

Warrants, economic lifetime

prqr_WarrantsEconomicLifetime

5 years

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2026
Document and Entity Information
Document Type	6-K
Document Period End Date	Mar. 31, 2026
Current Fiscal Year End Date	--12-31
Entity Registrant Name	ProQR Therapeutics N.V.
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001612940
Amendment Flag	false

General Information

3 Months Ended

Mar. 31, 2026

General Information

General Information

1. General Information

ProQR Therapeutics N.V., or “ProQR” or the “Company”, is a biotechnology company domiciled in the Netherlands that primarily focuses on the discovery and development of novel therapeutic medicines.

Since September 18, 2014, the Company’s ordinary shares have been listed on Nasdaq. They are currently trading at Nasdaq Capital Market under ticker symbol PRQR.

The Company was incorporated in the Netherlands, on February 21, 2012 (Chamber of Commerce no. 54600790) and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.

ProQR Therapeutics N.V. is the ultimate parent company of the following entities:

●	ProQR Therapeutics Holding B.V. (100%);

●	ProQR Therapeutics I B.V. (100%);

●	ProQR Therapeutics II B.V. (100%);

●	ProQR Therapeutics III B.V. (100%);

●	ProQR Therapeutics IV B.V. (100%);

●	ProQR Therapeutics V B.V. (100%);

●	ProQR Therapeutics VI B.V. (100%);

●	ProQR Therapeutics VII B.V. (100%);

●	ProQR Therapeutics VIII B.V. (100%);

●	ProQR Therapeutics IX B.V. (100%);

●	ProQR Therapeutics I Inc. (100%)

ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (“ESOP Foundation”) and has full control over this entity.

As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to “ProQR” or the “Company” refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.

Other Income (Tables)

3 Months Ended

Mar. 31, 2026

Other Income

Schedule of other income


		Three month period
		ended March 31,
		2026	2025
		€1,000	€1,000

Grant income		—	222
Total		—	222

Other Income - Narrative (Details) € in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025 EUR (€)	Dec. 31, 2024 USD ($)	Jan. 31, 2024 EUR (€)
Other Income [Line Items]
Grant income	€ 222
Maximum grant receivable for the initial phase of the project			€ 1,015
Maximum grant receivable for additional phase of the project \| $		$ 8,150

Other Income (Details) € in Thousands	3 Months Ended
Other Income (Details) € in Thousands	Mar. 31, 2025 EUR (€)
Other Income
Grant income	€ 222

Deferred Income (Tables)

3 Months Ended

Mar. 31, 2026

Deferred Income

Summary of deferred income


	March 31,	December 31,
	2026	2025
	€1,000	€1,000

Payments from Eli Lilly and Company	19,607	17,552
Payments from Rett Syndrome Research Trust	—	—
Current portion	19,607	17,552

Payments from Eli Lilly and Company	17,307	21,394
Non-current portion	17,307	21,394

Total	36,914	38,946

Significant Accounting Policies (Details)	3 Months Ended
Significant Accounting Policies (Details)	Mar. 31, 2026 segment
Significant Accounting Policies
Number of reportable segment	1

Print Document
Reports Document and Entity Information General Information Tables Deferred Income (Tables) Other Income (Tables) Details Significant Accounting Policies (Details) Other Income (Details) Other Income - Narrative (Details) Investments in Financial Assets (Details) Uncategorized Uncategorized Items - prqr-20260331xex99d1_htm.xml All Reports